Metsera: Capturing Of Obesity Market With Long-Acting GLP-1 Differentiation
Metsera's IPO raised $316.2 million, funding its obesity drug MET-097i, which shows promise with once-monthly dosing. Read ...
Metsera started by Guggenheim at buy on obesity drug opportunity
Guggenheim has initiated coverage of Metsera (MTSR) with a buy rating, citing the company's obesity drug candidates. Read ...
Metsera To Present At TD Cowen’S 45Th Annual Health Care Conference
A live webcast of the presentation will be available on the Events page in the Investors & News section of the Metsera website at investors.metsera.com . A replay of the webcast will be available for ...
The Crypto Basic on MSN4h
Bitcoin Adoption Rallies as 80% More Public Companies Bought in 2024: Report
The rate at which corporate and private institutions adopt the Bitcoin standard has surged extensively in the past year as ...